Immunicum

Immunicum is a clinical-stage immuno-oncology business established in Stockholm in 2002 with a primary goal of creating allogeneic dendritic cell technology. Based on research initially conducted at Sahlgrenska University Hospital in Gothenburg. Immunicum works to strengthen a patient's immune system so it can combat cancer, which improves survival rates and quality of life. Ilixadencel, the company's flagship product, is made up of allogeneic pro-inflammatory dendritic cells.

Immunicum anticipates the Phase II MERECA kidney cancer study results in 2019, marking a significant clinical advancement for the drug ilixadencel and the business. There are 88 patients in all in both Europe and the US for this company's first comparative trial. According to CEO de Sousa, "we see a potential for ilixadencel to become a backbone therapy in several future immunotherapies" because it "can be produced and stored for extended periods, and their data indicates that it might enhance the effect of different classes of I/O-drugs, like checkpoint inhibitors, immune enhancers, and other targeted therapies." In 2013, Immunicum debuted on the Nasdaq Stockholm.

Founded: 2002

Headquarters: Stockholm, Sweden

Website: https://mendus.com/